IFx-Hu2.0
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for IFx-Hu2.0, covering 2024-08-02 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma [Phase 2, Phase 3]